Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

Standard Dose
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER is listed in Drugs@FDA under application 206056 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient PIPERACILLIN SODIUM; TAZOBACTAM SODIUM Form and strength POWDER;INTRAVENOUS - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL Sponsor B BRAUN MEDICAL Submission history Latest submission status date: 2025-04-03 00:00:00.

Structured Monograph

Clinical summary

Approval overview PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER is listed in Drugs@FDA under application 206056 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient PIPERACILLIN SODIUM; TAZOBACTAM SODIUM Form and strength POWDER;INTRAVENOUS - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL Sponsor B BRAUN MEDICAL Submission history Latest submission status date: 2025-04-03 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.